Picking the right exit
Attributes that support an IPO exit:
• Proof-of-concept clinical data on lead drug candidate - typically robust Phase IIb or later data that provide substantial evidence of efficacy and safety.
• Legacy pharmaceutical partner to provide validation.
• Defined near- to intermediate-term news flow, with clear data points and events that will drive stock price accretion for new investors.
• Drug candidate that addresses large potential market opportunity